簡介:Ko 143是有效且選擇性的ATP結(jié)合盒亞家族G成員2 (ABCG2) 抑制劑。
Ko 143物理化學(xué)性質(zhì):
密度 |
1.2±0.1 g/cm3 |
沸點(diǎn) |
689.8±55.0 °C at 760 mmHg |
熔點(diǎn) |
147oC |
分子式 |
C26H35N3O5 |
分子量 |
469.573 |
閃點(diǎn) |
371.0±31.5 °C |
精確質(zhì)量 |
469.2577 |
PSA |
100.73 |
LogP |
2.42 |
蒸汽壓 |
0.0±2.2 mmHg at 25°C |
折射率 |
1.597 |
Ko 143詳細(xì)介紹:
中文名稱: |
(3S,6S,12aS)-1,2,3,4,6,7,12,12a-八氫-9-甲氧基-6-(2-甲基丙基)-1,4-二氧代吡嗪并[1',2':1,6]吡啶并[3,4-b]吲哚-3-丙酸叔丁酯 |
中文別名: |
(3S,6S,12aS)-1,2,3,4,6,7,12,12a-八氫-9-甲氧基-6-(2-甲基丙基)-1,4-二氧代吡嗪并[1',2':1,6]吡啶并[3,4-b]吲哚-3-丙酸叔丁酯;(3S,6S,12aS)-八氫-9-甲氧基-6-(2-甲基丙基)-1,4-二氧吡嗪并[1′,2′:1,6]吡啶并[3,4-b]吲哚-3-羧酸叔丁酯;(3S,6S,12aS)-八氫-9-甲氧基-6-(2-甲基丙基)-1,4-二氧吡嗪并[1'',2'':1,6]吡啶并[3,4-b]吲哚-3-羧酸叔丁酯;(3S,6S,12aS)-八氫-9-甲氧基-6-(2-甲基丙基)-1,4-二氧吡嗪并[1,2:1,6]吡啶并[3,4-b]吲哚-3-羧酸叔丁酯;(3S,6S,12AS)-八氫-9-甲氧基-6-(2-甲基丙基)-1,4-二氧吡嗪并[1',2':1,6]吡啶并[3,4-B]吲哚-3-羧酸叔丁酯 |
英文名稱: |
Tert-Butyl 3-((3S,6S,12aS)-6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)propanoate |
英文別名: |
tert-Butyl 3-((3S,6S,12aS)-6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl)propanoate;Ko 143;Ko143 hydrate;tert-Butyl 3-((3S,6S,12aS)-6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7, 12,12a-octahydropyrazino[1',2':1,6]pyrido[3,4-b]...;Ko-143;(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester;Ko143;C26H35N3O5;GTPL10007;Ko 143/Ko143;6345AB;ABP000297;BDBM50305083 |
CAS號: |
461054-93-3 |
分子式: |
C26H35N3O5 |
分子量: |
469.57 |
詳細(xì)描述 |
博飛美科提供461054-93-3,Ko 143,Medlife,上?,F(xiàn)貨。 Medlife,致力于提供高品質(zhì)、高性價(jià)比小分子化合物的產(chǎn)品。 Medlife小分子化合物大量庫存,提供超過2萬種的抑制劑、激動劑、拮抗劑等產(chǎn)品,是藥物及疾病研究的重要原料供應(yīng)商。 BCRP抑制劑,Ko 143是有效且選擇性的ATP結(jié)合盒亞家族G成員2 (ABCG2) 抑制劑。 查詢關(guān)鍵詞:“461054-93-3,Ko 143,PC14780,Medlife,上?,F(xiàn)貨”。 |
Ko 143參考文獻(xiàn):
[1]. Weidner LD, et al. The Inhibitor Ko143 Is Not Specific for ABCG2. J Pharmacol Exp Ther. 2015 Sep;354(3):384-93.
[2]. JD Allen et al. Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C. Mol. Cancer Ther. 2002, 1, 417-425.
[3]. Wen JH, et al. Effect of Ursolic Acid on Breast Cancer Resistance Protein-mediated Transport of Rosuvastatin In Vivo and Vitro. Chin Med Sci J. 2015 Dec;30(4):218-25.
[4]. Hou J, et al. Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012 Jul;66:232-9.
[5]. Liu K, et al. Metabolism of KO143, an ABCG2 inhibitor. Drug Metab Pharmacokinet. 2017 Aug;32(4):193-200.
產(chǎn)品技術(shù)規(guī)格說明書由上海創(chuàng)賽科技有限公司收集整理,僅作參考使用。